Laboratory Tests for Crohn's Disease Flare-Up

Essential Laboratory Panel

The American Gastroenterological Association recommends a complete blood count with differential to assess for anemia, leukocytosis, and thrombocytosis in patients with suspected Crohn's disease flare-up 1, 2, 3
C-reactive protein (CRP) is the preferred inflammatory marker as it is more sensitive than ESR and correlates better with endoscopic disease activity in Crohn's disease 1, 4
Erythrocyte sedimentation rate (ESR) provides complementary inflammatory assessment, though less sensitive than CRP 1, 2
Serum albumin and pre-albumin are used to assess nutritional status and degree of inflammation 1, 2
A comprehensive metabolic panel, including electrolytes, liver enzymes, and renal function, is essential for patients with suspected Crohn's disease flare-up 1, 3, 4
Iron studies are necessary to evaluate for iron deficiency anemia in patients with Crohn's disease 5, 6

Fecal calprotectin correlates better with endoscopic inflammation than CRP or white blood cell count, and is useful in assessing disease activity 5, 6
Stool cultures are mandatory to exclude bacterial pathogens in patients with suspected Crohn's disease flare-up 1, 2, 3
Clostridium difficile toxin test is necessary to rule out infectious triggers, as C. difficile can precipitate or mimic flares 1, 2, 3

A fecal calprotectin level of <150 mg/g effectively rules out active inflammation in asymptomatic patients, with a sensitivity of 81% and specificity of 72% 7
A fecal calprotectin level of >250 mg/g suggests endoscopically active disease, though confirmation with endoscopy is recommended before treatment escalation 7, 8
CRP >5 mg/L in symptomatic patients with moderate to severe symptoms suggests endoscopic activity and may preclude routine endoscopic assessment 8
Normal CRP (<5 mg/L) in asymptomatic patients helps rule out active inflammation 8

Biomarkers alone are insufficient in mildly symptomatic patients, and neither normal nor elevated biomarkers accurately determine endoscopic activity in this setting 8
Discordance between symptoms and biomarkers merits endoscopic evaluation for confirmation 8
CRP correlates better with endoscopic disease activity in Crohn's disease than in ulcerative colitis 1, 4
The combination of elevated CRP and fecal calprotectin provides the most reliable assessment of inflammatory activity 5, 6

A biomarker- and symptom-based monitoring strategy is superior to symptoms alone for patients in symptomatic remission, according to the 2023 AGA guidelines 8
In asymptomatic patients, fecal calprotectin <150 mg/g and normal CRP reliably rule out active inflammation, avoiding unnecessary endoscopy 8
In symptomatic patients with moderate to severe symptoms, elevated fecal calprotectin or CRP suggests endoscopic activity 8
Regular monitoring every 3-12 months as part of global disease assessment includes complete blood count, liver profile, albumin, iron studies, renal function, CRP, and fecal calprotectin 5, 6